Evaluation of serum and salivary transforming growth factor beta, vascular endothelial growth factor and tumor necrosis factor alpha in oral lichen planus.

• Main Authors: Amira Abdelwhab Abdelghaffar, Mahmoud Mohamed Kandeel, Hala Hassan Yassin, Wesam Abdelmonem, Olfat Gamil Shaker
• Format: Article
• Language: English
• Published: Universidad de Concepción. 2020-04-01
• Series: Journal of Oral Research
• Subjects: ral lichen planus; serum; saliva; transforming growth factor beta; vascular endothelial growth factor a; tumor necrosis factor-alpha
• Online Access: http://www.joralres.com/index.php/JOR/article/view/joralres.2020.012/728
• ISSN: 0719-2460; 0719-2479

Introduction: Lichen planus is one of the most common oral mucosal lesions. Transforming growth factor-β (TGF- β) has a marked effect on epithelial–mesenchymal transition and immune cells function. Vascular Endothelial Growth Factor (VEGF) is a key regulator of vasculogenesis and angiogenesis. Tumor necrosis factor-α (TNF-α) mediates T-lymphocyte homing and apoptosis of epithelial cells. Objetive: The present study was conducted in order to compare the expression of serum and salivary TGF- β, VEGF, TNF-α between OLP patients and control individuals to investigate if saliva can be used as an alternative to serum for diagnostic purposes and for monitoring disease. Materials and Methods: 23 OLP patients and 23 control individuals were included to evaluate serum and salivary TGF-β, VEGF, TNF-α using ELISA kits. Five milliliters of venous blood was collected and unstimulated saliva was collected by the spitting method. Results: Serum and salivary levels of TGF- β, VEGF, TNF-α are higher in OLP patients compared to normal controls. Mean difference is higher in saliva than serum. Moreover, there was a significant difference in serum and salivary VEGF and TNF-α between symptomatic and asymptomatic groups. Conclusions: Saliva can be a used as a substitute for serum to evaluate levels of the assessed biomarkers.